Compare PMTS & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | SAVA |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.1M | 156.5M |
| IPO Year | 2015 | N/A |
| Metric | PMTS | SAVA |
|---|---|---|
| Price | $13.73 | $2.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $32.00 | $5.00 |
| AVG Volume (30 Days) | 42.3K | ★ 1.0M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $515,576,000.00 | N/A |
| Revenue This Year | $13.70 | N/A |
| Revenue Next Year | $8.51 | N/A |
| P/E Ratio | $11.53 | ★ N/A |
| Revenue Growth | ★ 12.48 | N/A |
| 52 Week Low | $11.64 | $1.15 |
| 52 Week High | $34.25 | $4.98 |
| Indicator | PMTS | SAVA |
|---|---|---|
| Relative Strength Index (RSI) | 36.24 | 36.59 |
| Support Level | $13.61 | $1.96 |
| Resistance Level | $14.83 | $2.28 |
| Average True Range (ATR) | 0.56 | 0.15 |
| MACD | -0.24 | 0.01 |
| Stochastic Oscillator | 4.26 | 22.15 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.